Cargando…
Efficacy of anakinra on rebound of multisystem inflammatory syndrome
Autores principales: | Brisca, Giacomo, Olcese, Camilla, Derchi, Maria Elena, Trocchio, Gianluca, Caorsi, Roberta, Moscatelli, Andrea, Gattorno, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828510/ https://www.ncbi.nlm.nih.gov/pubmed/36331228 http://dx.doi.org/10.1111/ped.15337 |
Ejemplares similares
-
Cardiovascular Manifestations in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 According to Age
por: Campanello, Claudia, et al.
Publicado: (2022) -
Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Bhat, Chandrika S., et al.
Publicado: (2021) -
Protection against MIS-C outweighs the risk of myocarditis after Covid-19 vaccination in children
por: Mariani, Marcello, et al.
Publicado: (2022) -
Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C: Proposal for a Severity Score
por: Brisca, Giacomo, et al.
Publicado: (2021) -
Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia
por: Pontali, Emanuele, et al.
Publicado: (2021)